Archive - February 2018
FDA Approves Imfinzi (durvalumab) for Unresectable Stage III Non-Small Cell Lung Cancer
FDA Expands Approval of Imfinzi (durvalumab) to Reduce the Risk of Non-Small Cell Lung Cancer Progressing
http://www.pharmexec.com/digital-innovation-staying-ahead-curve
Multiple Artificial Intelligence Bills Introduced in House and Senate
Celgene spinoff raises $250M to develop placenta cells
Vertex cancels plans for CF triple combo testing in France, citing failed Orkambi negotiations
Could a Blood Thinner Actually Raise Stroke Risk for Some?
Ascension says it’s nearing finish line in Presence acquisition